CSL Behring announced the launch of Idelvion (coagulation factor IX [recombinant], albumin fusion protein) for the treatment of hemophilia B. This is the first factor IX therapy that allows up to 14-day dosing in select patients aged ≥12 years.
Idelvion was approved earlier this month for use in adults and children with hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on-demand control and prevention of bleeding episodes; and the perioperative management of bleeding.
Idelvion contains genetically fused recombinant coagulation Factor IX and recombinant albumin. Fusion with recombinant albumin extends the half-life of Factor IX. The 14-day dosing interval was able to maintain high factor activity of >5% at 75 IU/kg.
Idelvion is supplied in 250 IU, 500 IU, 1000 IU, and 2000 IU vial sizes.
For more information call (866) 915-6958 or visit Idelvion.com.